January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

An international trial is testing remternetug in young adults at genetic risk for early-onset Alzheimer’s. The study aims to ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between 7 February and, at the latest, 31 December 2024. This second tranche of ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

Eli Lilly says a new starting dose regimen for ... Simply shifting one vial of the anti-amyloid antibody from the first infusion to the third infusion of the titration phase of dosing – the ...